Impact of ligand binding on VEGFR1, VEGFR2, and NRP1 localization in human endothelial cells
Fig 5
Distribution of ligands and of active ligated VEGF receptors.
A, B, Levels of active VEGFR1 and VEGFR2 on the cell surface and internally, following 1 hour (A) or 4 hour (B) treatment with 50 ng.mL-1 of VEGF165a, VEGF121a, PLGF1, or PLGF2. C, D, Concentration of extracellular ligand (“surface”) and intracellular ligand (“internal”) following 1 hour (C) or 4 hour (D) treatment with 50 ng.mL-1 of VEGF165a, VEGF121a, PLGF1, or PLGF2. See the dose-dependent impacts on these levels in S13 and S14 Figs.